- Conditions
- Prostate Cancer
- Interventions
- Sipuleucel-T
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Marina del Rey, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 11,398
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Cancer
- Interventions
- amifostine trihydrate, carboplatin, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Interventions
- Alfuzosin (SL770499)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 55 Years and older · Male only
- Enrollment
- 1,522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
- Conditions
- HIV Infections
- Interventions
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
- Conditions
- Fabry Disease
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 1 Day to 90 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Hypertension
- Interventions
- Rheos® Baroreflex Hypertension System
- Device
- Lead sponsor
- CVRx, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
- Conditions
- Smoking
- Interventions
- ACT, CBT
- Behavioral
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Chronocort
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
- Conditions
- ICU Acquired Weakness
- Interventions
- FDY-5301, Placebo
- Drug · Other
- Lead sponsor
- Faraday Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Jolla, California + 24 more
- Conditions
- Cytomegalovirus Infections, Heart Transplantation
- Interventions
- valganciclovir [Valcyte]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 124 Days
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- Loma Linda, California • Palo Alto, California • Aurora, Colorado + 13 more
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- JCAR017, Lymphodepleting, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Up to 25 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 9
- States / cities
- Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
- Conditions
- Cytomegalovirus Infection
- Interventions
- Brincidofovir, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Crohn's Disease
- Interventions
- Abrilumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Interventions
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis, Phenelzine Sulfate
- Procedure · Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Solid Tumor
- Interventions
- SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 9
- States / cities
- Newark, Delaware • Iowa City, Iowa • Westwood, Kansas + 6 more
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
- Interventions
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 82
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
- Conditions
- Autistic Disorder
- Interventions
- Fluoxetine, Placebo
- Drug
- Lead sponsor
- Neuropharm
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 14 more
- Conditions
- Acute Appendicitis
- Interventions
- Patients with acute appendicitis
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- CPI 613, mFolfirinox, Folfirinox
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
- Conditions
- Acute Pain, Hyperalgesia
- Interventions
- IV acetaminophen, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Blood Coagulation Disorders
- Interventions
- FFP Infusion
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 4 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 11 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 110
- States / cities
- Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more